BioLineRx Ltd (BLRX)

0.925
+0.029(+3.24%)
After Hours
0.925
0.000(0.00%)
- Real-time Data
  • Volume:
    175,075
  • Day's Range:
    0.900 - 0.945
  • 52 wk Range:
    0.840 - 3.150

BLRX Overview

Prev. Close
0.896
Day's Range
0.9-0.945
Revenue
-
Open
0.9
52 wk Range
0.84-3.15
EPS
-0.031
Volume
175,075
Market Cap
56.43M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
223,504
P/E Ratio
-3.76
Beta
1.4
1-Year Change
-66.85%
Shares Outstanding
922,867,375
Next Earnings Date
Nov 16, 2022
What is your sentiment on BioLineRx?
or
Market is currently closed. Voting is open during market hours.

BioLineRx Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

BioLineRx Ltd Analysis

BioLineRx Ltd Company Profile

BioLineRx Ltd Company Profile

Employees
38

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralSellStrong Sell
Technical IndicatorsBuyStrong SellStrong BuyStrong SellStrong Sell
SummaryStrong BuyNeutralBuyStrong SellStrong Sell
  • BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
    0
    • They get fda fast track!!!
      1
      • Now it looks like my lucky ticket to the moon 🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝
        0
        • Get ready for the plane's take-off.
          0
          • I will not be a surprise, if this stock goes with 3 digit figures in the long run. lots of potential is hidden and should bustout anytime.
            0
            • journey begins...
              0
          • https://www.tipranks.com/stocks/blrx/forecast
            0
            • Do they really had good results ?The stock behavior say otherwise
              0
              • they will file for approval early next year, hopefully this will help it pick up again
                0
                • BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment
                  0
                  • Any chance that the result was overrated? How is us market reacting to the results?
                    0
                  • Dong ThreeThousandNot overrated
                    0
                  • If so this can hit $30 with ease
                    0
                • Only me?
                  0
                  • What r the reactions to the news? On US?
                    0